SCHEMBL60559

SCHEMBL60559

CCCCC[CH]C1=CCCC1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.33
MGLL Q99685 1/20 0.33
TSHR P16473 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9214217 0.98 TSHR (0.34) FAAHMGLLTSHR
SCHEMBL9205178 0.98 TSHR (0.34) FAAHMGLLTSHR
SCHEMBL9204392 0.98 TSHR (0.34) FAAHMGLLTSHR
SCHEMBL9210930 0.98 TSHR (0.34) FAAHMGLLTSHR
SCHEMBL62014 0.98 TSHR (0.34) FAAHMGLLTSHR
SCHEMBL9207844 0.98 TSHR (0.34) FAAHMGLLTSHR
SCHEMBL9211200 0.94 FAAH (0.33) FAAHMGLLTSHR
SCHEMBL9213136 0.94 TSHR (0.30) TSHR
SCHEMBL61668 0.93 TSHR (0.33) FAAHMGLLTSHR
SCHEMBL791251 0.89 PSMB5 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218633-A1 METHODS OF TREATING ORAL MUCOSITIS GALERA LABS, LLC 2023-07-13 US disclosed
US-11612608-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2023-03-28 US disclosed
US-11186560-B2 Arthropod repellent chemicals THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-11-30 US disclosed
US-20200215077-A1 METHODS OF TREATING ORAL MUCOSITIS BIOSSIL INC. (CA) 2020-07-09 US disclosed
US-10610533-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2020-04-07 US disclosed
EP-3527079-A1 METHODS OF TREATING ORAL MUCOSITIS Galera Labs, LLC (US) 2019-08-21 EP disclosed
US-20190194158-A1 ARTHROPOD REPELLENT CHEMICALS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-06-27 US disclosed
EP-2056675-B1 METHODS OF TREATING ORAL MUCOSITIS GALERA LABS LLC (US) 2019-01-09 EP disclosed
US-20180333421-A1 METHODS OF TREATING ORAL MUCOSITIS BIOSSIL INC. (CA) 2018-11-22 US disclosed
EP-3287464-A1 ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS Abbott Laboratories (US) 2018-02-28 EP disclosed
WO-1996040658-A1 PROCESS FOR PREPARING SUBSTITUTED POLYAZAMACROCYCLES MONSANTO COMPANY (US) 1996-12-19 WO disclosed
WO-1996039396-A1 MANGANESE OR IRON COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE MONSANTO COMPANY (US) 1996-12-12 WO disclosed
WO-1995028968-A1 DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES MONSANTO COMPANY (US) 1995-11-02 WO disclosed
EP-0421441-B1 Pantothenic acid derivatives FUJIREBIO KK (JP) 1995-01-25 EP disclosed
WO-1994015925-A1 MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE MONSANTO COMPANY (US) 1994-07-21 WO disclosed
EP-0598753-A1 MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE MONSANTO COMPANY (US) 1994-06-01 EP disclosed
WO-1993002090-A1 MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE MONSANTO COMPANY (US) 1993-02-04 WO disclosed
EP-0524161-A1 Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide MONSANTO COMPANY (US) 1993-01-20 EP disclosed
US-5120738-A Cardiovascular disorders FUJIREBIO INC. (JP) 1992-06-09 US disclosed
EP-0421441-A2 Pantothenic acid derivatives FUJIREBIO INC. (JP) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180333421-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO FAAH 3604/4885MGLL 1180/4885TSHR 4467/4885
US-20190194158-A1 ARTHROPOD REPELLENT CHEMICALS DDT, TRPA1, DHODH FAAH 326/4885MGLL 2097/4885TSHR 1742/4885
US-20200215077-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO FAAH 3604/4885MGLL 1180/4885TSHR 4467/4885
US-11186560-B2 Arthropod repellent chemicals DDT, TRPA1, DHODH FAAH 326/4885MGLL 2097/4885TSHR 1742/4885
US-20230218633-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO FAAH 3604/4885MGLL 1180/4885TSHR 4467/4885
US-10610533-B2 Methods of treating oral mucositis LPO, SOD3, MPO FAAH 3604/4885MGLL 1180/4885TSHR 4467/4885
US-11612608-B2 Methods of treating oral mucositis LPO, SOD3, MPO FAAH 3604/4885MGLL 1180/4885TSHR 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.